Abstract
When coadministered spinally, morphine and clonidine interact synergistically to produce antinociception. The mechanism for the synergism is unknown, but may depend on intracellular messenger systems. Agents that alter the activities of protein kinases alter antinociception produced by opioids, but their effects on clonidine-induced antinociception or the morphine/clonidine interaction are not known. In these studies, mice were pretreated intrathecally with inhibitors or activators of protein kinase C and cyclic AMP-dependent protein kinase (protein kinase A). Antinociceptive responses to intrathecally administered morphine, clonidine and morphine/clonidine combinations were then measured in the radiant heat tail flick test. Inhibition of protein kinase C activity with chelerythrine or calphostin C changed the morphine/clonidine interaction from synergistic to additive. Inhibition of protein kinase A activity with H-89 did not alter the morphine/clonidine interaction, it remained synergistic. Stimulation of protein kinase C activity with phorbol 12,13-dibutyrate attenuated morphine antinociception, but did not alter the synergistic interaction. Increasing spinal cyclic AMP concentrations with either forskolin or rolipram attenuated the antinociception produced by separately administered morphine and clonidine, but had no effect on the morphine/clonidine interaction. These results suggest that protein kinase C activity may regulate the interaction between spinal opioid and alpha-2 receptors, stimulated by morphine and clonidine.
Footnotes
-
Send reprint requests to: Dr. Sandra C. Roerig, Department of Pharmacology, Louisiana State University Medical Center, 1501 Kings Highway, Shreveport, LA 71130.
-
↵1 This work was supported by National Institutes of Health Grant DA07972. A preliminary report of this work was presented at the International Narcotic Research Conference, July 1996.
-
↵2 Current address: Alcon Laboratories, Fort Worth, TX.
- Abbreviations:
- PKA
- protein kinase A
- PKC
- protein kinase C
- % MPE
- percent maximum possible effect
- PDBu
- phorbol 12,13-dibutyrate
- DMSO
- dimethyl sulfoxide
- cAMP
- cyclic AMP
- i.t.
- intrathecal
- i.c.v.
- intracerebroventricular
- DRG
- dorsal root ganglion
- ED50
- median effective dose
- Received March 9, 1998.
- Accepted July 7, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|